摘要
目的评估真实世界伊沙佐米治疗多发性骨髓瘤(MM)的疗效和安全性。方法回顾性分析2019年1月至2021年1月来自中国贫血东部协作组单位(无锡市人民医院等)伊沙佐米治疗72例MM患者的血液学、细胞遗传学及疗效、安全性等数据。结果难治/复发MM(RRMM)患者接受伊沙佐米的中位治疗周期为6.0(3.0,7.0)个,总体有效率(ORR)为56.5%;新诊断MM(NDMM)患者中位治疗周期为4.5(4.0,9.5)个,总体有效率为85.8%;转换维持治疗组患者中位治疗周期为5.0(3.0,8.0)个,其中25.8%的患者缓解程度加深;不良事件(AEs)的总体发生率为26.5%。结论在真实世界中,伊沙佐米对RRMM、NDMM或是维持转换MM患者,具有良好的疗效和安全性。
Objective To evaluate the efficacy and safety of Isazomib in a real-world clinical practice in Chinese patients with multiple myeloma.Methods It was a retrospective,multi-center,observational study.A tolal of 72 patients with MM treated with Isazomib—based regimens were enrolled in 9 hospitals from January 2019 to January 2021.Relevant information was recorded,including baseline information,cytogenetics,treatment regimens,curative effect and safety.Results The median treatment cycle of Relapsed and refractory(RR)MM patients treated with Isazomib—based regimens was 6.0(3.0,7.0),ORR was 56.5%;NDMM patients with a median treatment cycle was 4.5(4.0,9.5),ORR was 85.8%;The median treatment cycle of patients in the conversion treatment group was 5.0(3.0,8.0),25.8% of these patients had a further remission;The overall incidence of AEs is low(26.5%).Conclusion In the real world of China,Isazomib is effective and safe in MM patients.
作者
王婧
顾伟英
管俊
龙启强
李炳宗
徐昕
卢绪章
华海应
吴正东
徐敏
周新
WANG Jing;GUWei-ying;GUAN Jun;LONG Qi-qiang;LI Bing-zong;XU Xin;LU Xu-zhang;HUA Hai-ying;WU Zheng-dong;XU Min;ZHOU Xin(Department of Hematology,Wuxi People's Hospital,Wuxi 214023,China;不详)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2023年第1期52-57,68,共7页
Chinese Journal of Practical Internal Medicine
